missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human DHX38 (aa 329-428) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (100%), Rat (100%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-59525 (PA5-59525. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.
Specifications
Specifications
| Accession Number | Q92620 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9785 |
| Name | Human DHX38 (aa 329-428) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 5730550P09Rik; AI325984; ATP-dependent RNA helicase DHX38; AW540902; DDX38; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 38; DEAH (Asp-Glu-Ala-His) box polypeptide 38; DEAH box protein 38; DEAH-box helicase 38; DHX38; hPrp16; KIAA0224; mKIAA0224; pre-mRNA splicing factor 16; pre-mRNA splicing factor ATP-dependent RNA helicase PRP16; pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16; PRP16; PRP16 homolog of S.cerevisiae; PRPF16 |
| Common Name | DHX38 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction